专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08314212B2 Plasminogen receptor PLG-RKT and antibodies thereof 有权
标题翻译：纤溶酶原受体Plg-RKT及其抗体
公开(公告)号：US08314212B2
公开(公告)日：2012-11-20
申请号：US12866520
申请日：2009-02-06
申请人： Lindsey A. Miles , John Yates , Emily I. Chen , Nagyung Baik , Robert J. Parmer
发明人： Lindsey A. Miles , John Yates , Emily I. Chen , Nagyung Baik , Robert J. Parmer
IPC分类号： C07K16/00
CPC分类号： C07K14/745
摘要： The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-RKT, or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator and Lipoprotein(a). Plasminogen receptors function to modulate cell surface proteolysis and physiological and pathophysiological processes requiring cell migration, including, but not limited to, cell migration during inflammation, tissue remodeling, wound healing, tumor cell invasion and metastasis, skeletal myogenesis, neurite outgrowth. Plasminogen receptors also modulate apoptosis and cell death. The invention also relates to antibodies that inhibit plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator or Lipoprotein(a) binding to Plg-RKT and/or immunoreact with Plg-RKT.
摘要翻译：本发明涉及C9orf46同源物，一种新型鼠膜蛋白及其在人，小鼠和所有其他物种中的直向同源物，称为Plg-RKT或其类似物，以及分离方法。该分子的功能是结合纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活物和脂蛋白（a）。纤溶酶原受体起调节细胞表面蛋白水解和需要细胞迁移的生理和病理生理过程，包括但不限于炎症，组织重塑，伤口愈合，肿瘤细胞侵袭和转移，骨骼肌发生，神经突生长等过程中的细胞迁移。纤溶酶原受体也调节凋亡和细胞死亡。本发明还涉及抑制纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活物或脂蛋白（a）结合Plg-RKT和/或与Plg-RKT的免疫反应的抗体。

2. 发明申请

US20130039919A1 NOVEL PLASMINOGEN RECEPTOR, POLYPEPTIDES AND ANTIBODIES THEREOF 有权
标题翻译：新型PLASMINOGEN受体，多肽及其抗体
公开(公告)号：US20130039919A1
公开(公告)日：2013-02-14
申请号：US13653862
申请日：2012-10-17
申请人： Lindsey A. Miles , John Yates, III , Emily I. Chen , Nagyung Baik , Robert J. Parmer
发明人： Lindsey A. Miles , John Yates, III , Emily I. Chen , Nagyung Baik , Robert J. Parmer
IPC分类号： A61K39/395 , A61P9/00 , A61P35/00 , A61P35/04 , C07K16/28 , A61P29/00
CPC分类号： C07K14/745
摘要： The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-RKT, or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin 1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator and Lipoprotein(a). Plasminogen receptors function to modulate cell surface proteolysis and physiological and pathophysiological processes requiring cell migration, including, but not limited to, cell migration during inflammation, tissue remodeling, wound healing, tumor cell invasion and metastasis, skeletal myogenesis, neurite outgrowth. Plasminogen receptors also modulate apoptosis and cell death. The invention also relates to antibodies that inhibit plasminogen, plasminogen fragments such as angiostatin 1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator or Lipoprotein(a) binding to Plg-RKT and/or immunoreact with Plg-RKT.
摘要翻译：本发明涉及C9orf46同源物，一种新型鼠膜蛋白及其在人，小鼠和所有其他物种中的直向同源物，称为Plg-RKT或其类似物，以及分离方法。该分子的功能是结合纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活剂和脂蛋白（a）。纤溶酶原受体起调节细胞表面蛋白水解和需要细胞迁移的生理和病理生理过程，包括但不限于炎症，组织重塑，伤口愈合，肿瘤细胞侵袭和转移，骨骼肌发生，神经突生长等过程中的细胞迁移。纤溶酶原受体也调节凋亡和细胞死亡。本发明还涉及抑制纤溶酶原，纤溶酶原片段如血管抑素1和具有血管生成活性的其它纤溶酶原片段，组织纤溶酶原激活物或脂蛋白（a）结合Plg-RKT和/或与Plg-RKT的免疫反应的抗体。

3. 发明授权

US07935785B2 Selective substrates for matrix metalloproteinases 失效
标题翻译：基质金属蛋白酶的选择性底物
公开(公告)号：US07935785B2
公开(公告)日：2011-05-03
申请号：US12252160
申请日：2008-10-15
申请人： Jeffrey W. Smith , Emily I. Chen , Steven J. Kridel
发明人： Jeffrey W. Smith , Emily I. Chen , Steven J. Kridel
IPC分类号： C07K5/00 , C07K14/00
CPC分类号： A61K49/0021 , A61K47/64 , A61K49/0056 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C07K5/0823 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1019 , C07K5/1024 , C07K7/06 , C07K7/08 , C12Q1/37
摘要： The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety. Also provided is a method of preferentially directing a moiety to a site of MMP-9 activity by administering to a subject an effective amount of an isolated MMP-9 selective substrate polypeptide containing SEQ ID NO:44 linked to a moiety, and preferentially directing a moiety to a site of MT1-MMP activity by administering to a subject an effective amount of an isolated MT1-MMP selective substrate polypeptide containing SEQ ID NOS:36-40 linked to a moiety.
摘要翻译：本发明提供分离的MMP-2，MMP-9和MT1-MMP选择性底物多肽或功能肽模拟物。选择性底物多肽包含以下序列：MMP-2选择性底物多肽含有SEQ ID NO：1-27，含有SEQ ID NO：28-35的MMP-9选择性底物多肽，并且含有SEQ ID NOS的MT1-MMP选择性底物多肽：36-40。此外，本发明提供了通过向受试者施用有效量的与部分连接的含有SEQ ID NO：45-47的分离的MMP-2选择性底物多肽来优先将部分定向到MMP-2活性位点的方法。还提供了通过向受试者施用有效量的与部分连接的含有SEQ ID NO：44的分离的MMP-9选择性底物多肽，优先将一部分连接至部分MMP-9活性部位的方法，通过向受试者施用有效量的与部分连接的含有SEQ ID NO：36-40的分离的MT1-MMP选择性底物多肽，从而部分到MT1-MMP活性的位点。

4. 发明申请

US20100316648A1 NOVEL PLASMINOGEN RECEPTOR, POLYPEPTIDES AND ANTIBODIES THEREOF 有权
标题翻译：新型PLASMINOGEN受体，多肽及其抗体
公开(公告)号：US20100316648A1
公开(公告)日：2010-12-16
申请号：US12866520
申请日：2009-02-06
申请人： Lindsey A. Miles , John Yates , Emily I. Chen , Nagyung Baik , Robert J. Parmer
发明人： Lindsey A. Miles , John Yates , Emily I. Chen , Nagyung Baik , Robert J. Parmer
IPC分类号： A61K39/395 , C07K7/06 , C07K7/08 , C07K14/745 , C07K16/36 , A61K38/36 , G01N33/53 , A61P35/00
CPC分类号： C07K14/745
摘要： The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-RKT, or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator and Lipoprotein(a). Plasminogen receptors function to modulate cell surface proteolysis and physiological and pathophysiological processes requiring cell migration, including, but not limited to, cell migration during inflammation, tissue remodeling, wound healing, tumor cell invasion and metastasis, skeletal myogenesis, neurite outgrowth. Plasminogen receptors also modulate apoptosis and cell death. The invention also relates to antibodies that inhibit plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator or Lipoprotein(a) binding to Plg-RKT and/or immunoreact with Plg-RKT.
摘要翻译：本发明涉及C9orf46同源物，一种新型鼠膜蛋白及其在人，小鼠和所有其他物种中的直向同源物，称为Plg-RKT或其类似物，以及分离方法。该分子的功能是结合纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活物和脂蛋白（a）。纤溶酶原受体起调节细胞表面蛋白水解和需要细胞迁移的生理和病理生理过程，包括但不限于炎症，组织重塑，伤口愈合，肿瘤细胞侵袭和转移，骨骼肌发生，神经突生长等过程中的细胞迁移。纤溶酶原受体也调节凋亡和细胞死亡。本发明还涉及抑制纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活物或脂蛋白（a）结合Plg-RKT和/或与Plg-RKT的免疫反应的抗体。

5. 发明申请

US20090253896A1 SELECTIVE SUBSTRATES FOR MATRIX METALLOPROTEINASES 失效
标题翻译：基质金属选择性基体
公开(公告)号：US20090253896A1
公开(公告)日：2009-10-08
申请号：US12252160
申请日：2008-10-15
申请人： Jeffrey W. Smith , Emily I. Chen , Steven J. Kridel
发明人： Jeffrey W. Smith , Emily I. Chen , Steven J. Kridel
IPC分类号： C07K7/06
CPC分类号： A61K49/0021 , A61K47/64 , A61K49/0056 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C07K5/0823 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1019 , C07K5/1024 , C07K7/06 , C07K7/08 , C12Q1/37
摘要： The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety. Also provided is a method of preferentially directing a moiety to a site of MMP-9 activity by administering to a subject an effective amount of an isolated MMP-9 selective substrate polypeptide containing SEQ ID NO:44 linked to a moiety, and preferentially directing a moiety to a site of MT1-MMP activity by administering to a subject an effective amount of an isolated MT1-MMP selective substrate polypeptide containing SEQ ID NOS:36-40 linked to a moiety.
摘要翻译：本发明提供分离的MMP-2，MMP-9和MT1-MMP选择性底物多肽或功能肽模拟物。选择性底物多肽包含以下序列：MMP-2选择性底物多肽含有SEQ ID NO：1-27，含有SEQ ID NO：28-35的MMP-9选择性底物多肽，并且含有SEQ ID NOS的MT1-MMP选择性底物多肽：36-40。此外，本发明提供了通过向受试者施用有效量的与部分连接的含有SEQ ID NO：45-47的分离的MMP-2选择性底物多肽来优先将部分定向到MMP-2活性位点的方法。还提供了通过向受试者施用有效量的与部分连接的含有SEQ ID NO：44的分离的MMP-9选择性底物多肽，优先将一部分连接至部分MMP-9活性部位的方法，通过向受试者施用有效量的与部分连接的含有SEQ ID NO：36-40的分离的MT1-MMP选择性底物多肽，从而部分到MT1-MMP活性的位点。

6. 发明授权

US07439319B2 Selective substrates for matrix metalloproteinases 失效
标题翻译：基质金属蛋白酶的选择性底物
公开(公告)号：US07439319B2
公开(公告)日：2008-10-21
申请号：US10243613
申请日：2002-09-13
申请人： Jeffrey W. Smith , Emily I. Chen , Steven J. Kridel
发明人： Jeffrey W. Smith , Emily I. Chen , Steven J. Kridel
IPC分类号： A61K38/00 , C07K16/00
CPC分类号： A61K49/0021 , A61K47/64 , A61K49/0056 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C07K5/0823 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1019 , C07K5/1024 , C07K7/06 , C07K7/08 , C12Q1/37
摘要： The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety. Also provided is a method of preferentially directing a moiety to a site of MMP-9 activity by administering to a subject an effective amount of an isolated MMP-9 selective substrate polypeptide containing SEQ ID NO:44 linked to a moiety, and preferentially directing a moiety to a site of MT1-MMP activity by administering to a subject an effective amount of an isolated MT1-MMP selective substrate polypeptide containing SEQ ID NOS:36-40 linked to a moiety.
摘要翻译：本发明提供分离的MMP-2，MMP-9和MT1-MMP选择性底物多肽或功能肽模拟物。选择性底物多肽包含以下序列：MMP-2选择性底物多肽含有SEQ ID NO：1-27，含有SEQ ID NO：28-35的MMP-9选择性底物多肽，并且含有SEQ ID NOS的MT1-MMP选择性底物多肽：36-40。此外，本发明提供了通过向受试者施用有效量的与部分连接的含有SEQ ID NO：45-47的分离的MMP-2选择性底物多肽来优先将部分定向到MMP-2活性位点的方法。还提供了通过向受试者施用有效量的与部分连接的含有SEQ ID NO：44的分离的MMP-9选择性底物多肽，优先将一部分连接至部分MMP-9活性部位的方法，通过向受试者施用有效量的与部分连接的含有SEQ ID NO：36-40的分离的MT1-MMP选择性底物多肽，从而部分到MT1-MMP活性的位点。

7. 发明授权

US08680242B2 Plasminogen receptor, polypeptides and antibodies thereof 有权
标题翻译：纤溶酶原受体，多肽及其抗体
公开(公告)号：US08680242B2
公开(公告)日：2014-03-25
申请号：US13653862
申请日：2012-10-17
申请人： Lindsey A. Miles , John Yates , Emily I. Chen , Nagyung Baik , Robert J. Parmer
发明人： Lindsey A. Miles , John Yates , Emily I. Chen , Nagyung Baik , Robert J. Parmer
IPC分类号： C07K16/00
CPC分类号： C07K14/745
摘要： The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-RKT, or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator and Lipoprotein(a). Plasminogen receptors function to modulate cell surface proteolysis and physiological and pathophysiological processes requiring cell migration, including, but not limited to, cell migration during inflammation, tissue remodeling, wound healing, tumor cell invasion and metastasis, skeletal myogenesis, neurite outgrowth. Plasminogen receptors also modulate apoptosis and cell death. The invention also relates to antibodies that inhibit plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator or Lipoprotein(a) binding to Plg-RKT and/or immunoreact with Plg-RKT.
摘要翻译：本发明涉及C9orf46同源物，一种新型鼠膜蛋白及其在人，小鼠和所有其他物种中的直向同源物，称为Plg-RKT或其类似物，以及分离方法。该分子的功能是结合纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其他血浆纤溶酶片段，组织纤溶酶原激活物和脂蛋白（a）。纤溶酶原受体起调节细胞表面蛋白水解和需要细胞迁移的生理和病理生理过程，包括但不限于炎症，组织重塑，伤口愈合，肿瘤细胞侵袭和转移，骨骼肌发生，神经突生长等过程中的细胞迁移。纤溶酶原受体也调节凋亡和细胞死亡。本发明还涉及抑制纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其他血浆纤溶酶片段，组织纤溶酶原激活剂或脂蛋白（a）结合Plg-RKT和/或与Plg-RKT的免疫反应的抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式